BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists’ awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62:704-711. [PMID: 20461789 DOI: 10.1002/acr.20209] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
2 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
3 Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol. 2012;39:269-273. [PMID: 22077677 DOI: 10.1111/j.1346-8138.2011.01434.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
4 Takahashi T, Koike T, Hashimoto S, Miura T, Nakamura J, Yamada S, Miura T, Yanagi M, Yamazaki K, Okoshi S, Aoyagi Y. A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma. Hepatol Int 2009;3:316-22. [PMID: 19669383 DOI: 10.1007/s12072-008-9094-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:925-932. [PMID: 20480515 DOI: 10.1002/ibd.21284] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
6 Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. Gastroenterol Hepatol. 2010;33:377-381. [PMID: 20363054 DOI: 10.1016/j.gastrohep.2010.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Wang HS, Han SB. Management of Hepatitis B in Special Patient Populations. Clinics in Liver Disease 2010;14:505-20. [DOI: 10.1016/j.cld.2010.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wu JM, Huang YH, Lee PC, Lin HC, Lee SD. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol. 2009;43:496-498. [PMID: 19247200 DOI: 10.1097/mcg.0b013e3181945942] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
9 Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy--rare but there! Leuk Lymphoma. 2009;50:1083-1095. [PMID: 19399690 DOI: 10.1080/10428190902934944] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 7.4] [Reference Citation Analysis]
10 Gawande A, Gupta GK, Gupta A, Wanjari SJ, Goel V, Rathore V, Bhardwaj H, Nijhawan S. Acute-on-Chronic Liver Failure: Etiology of Chronic and Acute Precipitating Factors and Their Effect on Mortality. J Clin Exp Hepatol 2019;9:699-703. [PMID: 31889750 DOI: 10.1016/j.jceh.2019.04.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-82. [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x] [Cited by in Crossref: 537] [Cited by in F6Publishing: 509] [Article Influence: 41.3] [Reference Citation Analysis]
12 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
13 Chen D, Luo S, Ben Q, Lu L, Wan X, Wu J. Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China. Eur J Gastroenterol Hepatol. 2017;29:509-515. [PMID: 28350740 DOI: 10.1097/meg.0000000000000838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
15 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864-871. [PMID: 20546439 DOI: 10.1111/j.1440-1746.2010.06243.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
16 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 5.5] [Reference Citation Analysis]
17 Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013;20:200-8. [PMID: 23383659 DOI: 10.1111/j.1365-2893.2012.01643.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
18 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
19 Zhang GL, Zhang T, Ye YN, Liu J, Zhang XH, Xie C, Peng L, Gao ZL. Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure. Biomed Res Int 2016;2016:3524842. [PMID: 27144164 DOI: 10.1155/2016/3524842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
20 Eroglu Y, Byrne WJ. Hepatic encephalopathy. Emerg Med Clin North Am 2009;27:401-14. [PMID: 19646644 DOI: 10.1016/j.emc.2009.04.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
21 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
22 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 8.3] [Reference Citation Analysis]
23 Lei Z, Mo Z, Zhu J, Pang X, Zheng X, Wu Z, Wang K, Li X, Xie D, Gao Z. Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure. Mediators Inflamm 2015;2015:535938. [PMID: 25892854 DOI: 10.1155/2015/535938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
24 Gopal K, Min AD. Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant. Curr Hepatitis Rep 2010;9:178-86. [DOI: 10.1007/s11901-010-0048-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379-1385. [PMID: 22530631 DOI: 10.1111/j.1365-2036.2012.05110.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
26 Zand L, Specks U, Sethi S, Fervenza FC. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. Adv Chronic Kidney Dis. 2014;21:182-193. [PMID: 24602467 DOI: 10.1053/j.ackd.2014.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Caldera F, Ley D, Hayney MS, Farraye FA. Optimizing Immunization Strategies in Patients with IBD.Inflamm Bowel Dis. 2021;27:123-133. [PMID: 32232388 DOI: 10.1093/ibd/izaa055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
29 Duan Z, Kong Y, Zhang J, Guo H. Psychological comorbidities in Chinese patients with acute-on-chronic liver failure. General Hospital Psychiatry 2012;34:276-81. [DOI: 10.1016/j.genhosppsych.2011.11.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Zeng Y, Li Y, Xu Z, Gan W, Lu L, Huang X, Lin C. Myeloid-derived suppressor cells expansion is closely associated with disease severity and progression in HBV-related acute-on-chronic liver failure. J Med Virol. 2019;91:1510-1518. [PMID: 30905084 DOI: 10.1002/jmv.25466] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma. 2008;49:939-947. [PMID: 18464113 DOI: 10.1080/10428190801975568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
32 Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int 2015;9:224-30. [PMID: 25788197 DOI: 10.1007/s12072-015-9612-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
33 Gao S, Sun FK, Fan YC, Shi CH, Zhang ZH, Wang LY, Wang K. Aberrant GSTP1 promoter methylation predicts short-term prognosis in acute-on-chronic hepatitis B liver failure. Aliment Pharmacol Ther 2015;42:319-29. [PMID: 26040771 DOI: 10.1111/apt.13271] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
34 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
35 Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opinion on Pharmacotherapy 2010;11:889-903. [DOI: 10.1517/14656561003642006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Pati GK, Singh A, Misra B, Misra D, Das HS, Panda C, Singh SP. Acute-on-Chronic Liver Failure (ACLF) in Coastal Eastern India: "A Single-Center Experience". J Clin Exp Hepatol 2016;6:26-32. [PMID: 27194893 DOI: 10.1016/j.jceh.2015.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
37 Wang ZL, Gao S, Li L, Li XY, Huan SL, Wang K. Demethylation of tumor necrosis factor-α converting enzyme predicts poor prognosis in acute-on-chronic hepatitis B liver failure. Clin Res Hepatol Gastroenterol 2016;40:457-64. [PMID: 26850359 DOI: 10.1016/j.clinre.2015.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]